NSE-listed pharmaceutical and device companies investing in GLP-1 receptor agonist manufacturing — from peptide API production to semaglutide pen delivery systems.
Sectors represented: Healthcare
So it's a doubling of capacity that we have just. completed, and we will go through the regulatory approval process to bring that product. to patients. manufacturing drug product twofold. So it's a doubling of capacity that we have just. completed, and we will go through the regulatory approval process to bring that product. to patients.
Now, we are waiting. for revert from U.S. FDA. Sanjay Kumar: Okay. Okay. Got it. And second, on you mentioned about a new peptide capacity. and CAPA responses are submitted to U.S. FDA. Now, we are waiting. for revert from U.S. FDA. Sanjay Kumar: Okay. Okay. Got it. And second, on you mentioned about a new peptide capacity. Do you.
Created a strategic stock of Insulins - consequent. working capital increase of Rs. 73 cr. in Q1 with an. impact on OCF for the quarter. . Bhopal vial manufacturing has been commissioned. after significant delays. . . Initiated supply of Insugen vials from MJ Biopharm's al increase of Rs. 73 cr. in Q1 with an. impact on OCF for the quarter. . Bhopal vial manufacturing has been commissioned.
It would take some time for us to completely utilize 140 million. But this is. what the visibility as of now. Srinivas Sadu:. So as of now capacity is 40 million just to be clear, and then 100 million is getting added this. year. us to completely utilize 140 million. But this is. what the visibility as of now. Srinivas Sadu:.
Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹89.898 and accordingly the prior period figures have been restated. 1. de fully provided in. FY26 financials. Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹89.898 and accordingly the prior period figures have been restated. 1.
Unique competitive edge with GLP-1 is a significant factor for future success while the biologics. business has also picked up. 33. ▷FromalowbaseinFY20,wehaveaddedseveralnew. customersafterreceivingUSFDAapprovalinFY23(Two. inspectionsincludedinCY2022-PAI,DrugDevice,andGMP). ▷Ourbusinesscontinuestogrowaswepropelourgeographical. marketingeffortsandattractnewpartners.
So, to begin with, let's talk about the healthcare. So, Amit, I would like to take. what are your customers talking about. anjay bhai. Great set of numbers and certain milestones. in this quarter. So, to begin with, let's talk about the healthcare. So, Amit, I would like to take. what are your customers talking about. So basically, what I'm trying to understand, are your.
Erez Israeli: Yeah, I believe so. You can see that by the fact that Lenalidomide is going down, we are. maintaining reasonably low numbers. or this to. actually show up in numbers?. Erez Israeli: Yeah, I believe so. You can see that by the fact that Lenalidomide is going down, we are. maintaining reasonably low numbers. So, it's absolutely a reflection of those mitigations. Of.
New technologies; KSM & backward integration. Ascelis Peptides Lab. Peptide R&D at IIT Hyderabad. Senn Chemicals AG. Peptide CDMO R&D, Switzerland. 47. 21. 10. 12. 7. 55. 2. USEU CEPEU ASMFKoreaChinaCanadaBrazilJapan. Global DMF Filings (Total: 109) gration. Ascelis Peptides Lab. Peptide R&D at IIT Hyderabad. Senn Chemicals AG. Peptide CDMO R&D, Switzerland. 47. 21. 10. 12. 7. 55. 2.
GLP1 Agonists under development. Research and Development. Yeast, mammalian and bacterial platform. Drug substance manufacturing. 4 facilities. Drug product manufacturing. 2 facilities. Patented delivery device. Disposable Pen, Reusable Pen. Business Organization t. Yeast, mammalian and bacterial platform. Drug substance manufacturing. 4 facilities. Drug product manufacturing. 2 facilities.